Staff, Author at Green Market Report - Page 22 of 139

StaffMay 11, 2021


Aleafia Health Inc. (OTCQX: ALEAF) reported its financial results for the three months ended March 31, 2021. Revenue fell 55% from last year’s $13.7 million to this year’s $6.2 million. most of the decline was due to an 84% drop in bulk wholesale cannabis sales. Aleafia also reported that its net losses increased from last year’s $6.1 million to this year’s $11.2 million.

“This quarter saw us achieve important executional breakthroughs as we realized the exponential increase of our cannabis product portfolio. Likewise, as we benefit from greater scale, we are demonstrating substantial improvements in the profitability of our core adult-use and medical cannabis product sales, contrasting with the broader industry trend of price and margin compression,” said Aleafia Health CEO Geoffrey Benic.

“To further leverage product portfolio expansion, we have only just begun the deployment of our highly differentiated medical cannabis ecosystem through the trailblazing exclusive agreement with Unifor, Canada’s largest private sector union. The ability to service a captive audience of union members who receive insurance coverage for medical cannabis is an important catalyst. We believe that this sets the table for a strong 2021, driven by repeatable, profitable sales in the medical, adult-use and international markets.”

Revenue Breakdown

The company had warned investors that its wholesale business would decline and while its other cannabis increased, the numbers aren’t quite as large as the wholesale figures.

Medical cannabis net revenue increased 95% to $2.7 million, in line with the previous quarter, and the company’s best Canadian medical cannabis revenue reported to date. Active registered patients increased to 17,637, an increase of 61% over the prior year’s quarter. Medical cannabis adjusted gross margin before FV adjustments improved for the second consecutive quarter to 53%. Revenue per gram equivalent sold improved for the fourth consecutive quarter to $8.46

Adult-use cannabis net revenue rose 22% to $1.7 million and 143% over the previous quarter and prior year’s quarter respectively. Adult-use cannabis adjusted gross margin before FV adjustments improved substantially to 56%, from 31% and 30% in the previous quarter and prior year’s quarter respectively. Adult-use cannabis revenue in the first 41 days of the second has surpassed total adult-use cannabis revenue for the first quarter of 2021.

StaffMay 10, 2021


It’s time for your Daily Hit of cannabis financial news for May 10, 2021.

On The Site


Trulieve Cannabis Corp.  (OTC: TCNNF) is buying  Harvest Health & Recreation Inc.  (OTCQX: HRVSF) in a deal valued at approximately $2.1 billion based on the closing price of the Trulieve Shares on May 7, 2021. The combined businesses will have operations in 11 states, comprised of 22 cultivation and processing facilities with a total capacity of 3.1 million square feet, and 126 dispensaries serving both the medical and adult-use recreational cannabis markets.

Harvest Health

Harvest Health & Recreation Inc.  (OTCQX: HRVSF)  reported its financial and operating results for the first quarter of 2021 with revenue rising 101% to $88.8 million from $44.2 million in the first quarter of 2020. Revenue also rose sequentially by 27% from $69.9 million in the fourth quarter of 2020. This beat the average analyst estimate from Yahoo Finance for revenue of $87 million in the quarter. However, the company missed the estimate for the earnings loss which came in at ($0.06) per share while the estimate was for ($0.01.) per share. The net loss before non-controlling interest was $23.0 million for the first quarter, compared to $7.4 million in the fourth quarter of 2020. The adjusted EBITDA in the first quarter was $26.9 million, compared to $9.1 million in the fourth quarter of 2020.


Curaleaf Holdings, Inc. (OTCQX: CURLF) reported its financial and operating results for the first quarter ended March 31, 2021. Total revenue increased by 170% to $260 million during the first quarter of 2021, compared to $96 million in the first quarter of 2020. Despite the enormous revenues, Curaleaf still delivered a net loss in the quarter of $17 million, versus a net loss of $15 million in the first quarter of 2020.

The company attributed the loss to an income tax provision of $31 million and ultimately blamed it on Section 280E of the Internal Revenue Code and, to a lesser degree, by an increase in the interest expense related to lease liabilities due to the expanded number of retail sites. The net loss for the quarter also included approximately $6 million in one-time charges which mostly include expenses associated with the equity offering and debt raise. 

Flower One

Flower One Holdings Inc. (OTCQX: FLOOF) announced unaudited preliminary first-quarter revenue guidance of $13.5 million. Flower One said that it expects to announce the date for its filing of the fiscal 2020 year and first quarter 2021 in the coming weeks. The company hasn’t reported results since the third quarter ending in September 2020 when revenues were $11.9 million.

In Other News


Akerna (Nasdaq: KERN) reported its unaudited financial results for the quarter ended March 31, 2021. Total revenue was $4.0 million, up 31% year over year. Net loss was $6.3 million compared to a net loss of $4.8 million in the same period last year. “Our first quarter was a strong start to 2021, with increasing demand for our platform driving 62% year over year software growth,” said Jessica Billingsley, CEO of Akerna.  


Wesana Health Holdings Inc.  (CSE: WESA), formerly Debut Diamonds Inc.,  shares began trading on the Canadian Securities Exchange (“CSE”) today, Monday, May 10, 2021, under the ticker symbol “WESA.”

“Following the completion of our go public transaction, we’re thrilled to embark on this journey as a public company listing on the CSE. As a CSE listed company, we will be able to increase engagement with our shareholders and the investment community as we continue to execute on our mission to develop alternative treatment solutions for traumatic brain injury,” said Daniel Carcillo, CEO of Wesana Health.

StaffMay 10, 2021


Curaleaf Holdings, Inc. (OTCQX: CURLF) reported its financial and operating results for the first quarter ended March 31, 2021. Total revenue increased by 170% to $260 million during the first quarter of 2021, compared to $96 million in the first quarter of 2020. Despite the enormous revenues, Curaleaf still delivered a net loss in the quarter of $17 million, versus a net loss of $15 million in the first quarter of 2020.

The company attributed the loss to an income tax provision of $31 million and ultimately blamed it on Section 280E of the Internal Revenue Code and, to a lesser degree, by an increase in the interest expense related to lease liabilities due to the expanded number of retail sites. The net loss for the quarter also included approximately $6 million in one-time charges which mostly include expenses associated with the equity offering and debt raise.

“Curaleaf delivered record first quarter 2021 financial results with total revenue exceeding the high-end of our guidance range as we extended our U.S. leadership, all while creating a new foundation for future international growth opportunities,” said Joe Bayern , Chief Executive Officer. “The stronger than expected first-quarter performance drove record adjusted EBITDA as well as approximately 640 basis points of improvement in gross margin year-over-year. These impressive results reflect the leverage of the strategic investments we have made across the organization in cultivation, product innovation as well as expanding our branded retail and wholesale distribution channels. Curaleaf launched a range of innovative new products to our retail and wholesale channels during the quarter, including our new Select Squeeze THC-infused beverage enhancer which marked our most successful product launch ever and represented one of the cannabis industry’s widest national product launches to date. With our revenue projected to increase to $305 million to $315 million in the second quarter, we also expect to generate significant improvements in terms of achieving positive net income and positive operating cash flows in the back half of 2021.”

Revenue Grows Across The Board

Curaleaf noted that retail revenue increased by 231% to $188 million during the first quarter of 2021, compared to $57 million in the first quarter of 2020, representing 72% of total revenue. Growth in retail revenue was primarily due to strong organic growth across Curaleaf’s footprint, the opening of six new stores across FloridaMaine, and Pennsylvania, and the rapid acceleration of revenue growth in Arizona after the introduction of adult-use sales in January of 2021.

Wholesale revenue increased 254% to $72 million during the first quarter of 2021, compared to $20 million in the first quarter of 2020, representing 28% of total revenue. Growth in wholesale revenue was due primarily to the continued national expansion of the Select brand in both the Central and Northeastern markets including MassachusettsNew YorkNew JerseyMarylandIllinois, and Pennsylvania, and the successful launch of new products such as Select Squeeze, Select Essentials, and Select Fresh. It also resulted from the strength of the Select brand in core Western markets including ArizonaCalifornia, and Oregon.

Boris Jordan, Executive Chairman of Curaleaf said, “With the acceleration of cannabis liberalization momentum at the state and federal levels, Curaleaf’s prospects for growth in the United States have never been stronger. The recent approvals of adult-use cannabis in New Jersey and New York, which are states where Curaleaf has a leading market share, will unlock vast new markets, worth an estimated $2.1 billion and $5 billion in sales respectively. We raised approximately $300 million in new capital during the first quarter to help support our ability to scale for new adult-use markets while also allowing us to be opportunistic for highly attractive assets that further strengthen our position as the global cannabis market leader.”

StaffMay 10, 2021


Flower One Holdings Inc. (OTCQX: FLOOF) announced unaudited preliminary first-quarter revenue guidance of $13.5 million. Flower One said that it expects to announce the date for its filing of the fiscal 2020 year and first quarter 2021 in the coming weeks.

The company hasn’t reported results since the third quarter ending in September 2020 when revenues were $11.9 million.

“We are extremely proud of our team and the tremendous collaborative effort put forth by so many to successfully restructure Flower One and become the top producer in Nevada,” said Kellen O’Keefe, Flower One’s President and Interim CEO. “For us to have accomplished what we have under the circumstances was nothing short of remarkable and something our entire team can be very proud of. As a company, we have never been in a stronger position and will emerge from the pandemic a different company on an entirely new trajectory. We continue to break records month after month, ending April with all-time high monthly sales and the highest average selling price per pound in our company’s history. We are extremely well-positioned for future growth as Vegas comes back online; and, we welcome the first Cookies store to the strip this week.”

Flower One also reported that as of March 2021, it is the top flower provider in the state of Nevada, recognizing both the number one (Cookies) and number two (NLVO, the Company’s in-house brand) as top-selling flower brands in the state. The company said that in addition to holding the two top-selling flower brands, it is also the leading producer of distillate, bulk, and white label flower sales in the state of Nevada.

Other highlights in the company’s statement included:

  • The Company’s yielding cultivation analytics are reported up to 135.7 grams per plant through the first quarter of 2021, at an average cost per gram of USD$0.58. The Company has historically has reported its average cost per gram to be between USD$0.40-0.69;
  • Through updates to its post-harvesting process (drying, curing, trimming and packaging), the Company has recognized over 300% growth in its processing capacity in the first quarter of 2021, in comparison to the fourth quarter of 2020.

Debt Restructuring/ New CEO

In April, the company announced that it converted 60% of the principal amount of the Debentures for units comprised of one common share and ⅚ of a warrant- resulting in the total principal amount of the 9.5% unsecured debentures due March 28, 2022, being reduced from C$42,471,000 to C$16,988,400; and, the total principal amount of the 9.5% unsecured convertible debentures due November 15, 2022, being reduced from C$9,276,000 to C$3,710,400. The company had defaulted on payments such as $262,500 due on January 1, 2021 in connection with a loan from RB Loan Portfolio I, LLC  and lease payments in the amount of $526,677 due on January 5, 2021 in connection with the company’s lease of the greenhouse facility located at 3950 North Bruce Street in North Las Vegas.

In January Kellen O’Keefe was appointed from his previous position of Chief Strategy Officer to Flower One’s President and Interim Chief Executive Officer.

StaffMay 8, 2021


Editors Note: This is a guest post. 

Medical marijuana is now legal in more than two-thirds of the US and many countries worldwide, in contrast to recreational cannabis use, which is still frowned upon ―and for the greatest part remains illegal.   

And even though studies are being conducted regularly during the last decade, marijuana is still classified as a Schedule I substance. Hence, its use in clinical trials needs to be registered by the respective institution and approved by the Drug Enforcement Administration, and that inhibits faster progress in the research field.  

What is medical marijuana?  

The short answer is that medical marijuana is not materially different from what you get in the post when you buy weed online to enjoy with your buddies at the weekend. The main distinction is one of classification and purpose, which is, of course, important in states where medical weed is legal and recreational is not. Aside from that, medical weed usually has a higher CBD content, whereas the recreational variety will have higher THC. In other words, medical weed is not usually as “strong” and will be less likely to have you giggling uncontrollably or in a state of couch-lock.  

In general, all marijuana is derived from the Cannabis sativa or the Cannabis indica plant, and it contains more than a hundred different chemical compounds, also known as cannabinoids. When ingested or inhaled, cannabinoids attach to specific receptors of our body, relieving pain and easing discomfort, inflammation, etc. The most well-known and important cannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the compound known for its intoxicating effect, whereas CBD has no psychoactive properties whatsoever.

The main distinction between recreational and medical marijuana is one of classification and purpose. Medical marijuana contains three major active compounds: THC, CBD, and CBN (cannabinol, a by-product of THC); those compounds are found in different potencies and amounts in medical marijuana products, depending on the condition they treat. Of course, medical products have a higher CBD content and very low THC ―the legal limit being 0.3% in most cases.  

What is medical marijuana used for?  

The main thing to understand is that medical marijuana is not a cure for any condition: it’s basically an alternative to symptom-relieving drugs, like painkillers and opioids. More than two million medical marijuana patients have been recorded in the US. The most widely known reason is the plant’s anti-inflammatory properties, which can help relieve chronic pain caused by conditions like arthritis.   

Other uses include the treatment of epileptic seizures and depression. Easing chemotherapy-related nausea and appetite stimulation effects have also been confirmed. At the same time, the results from a 2014 study by the American Academy of Neurology indicate that medical marijuana may be beneficial in easing some of the symptoms caused by multiple sclerosis.  

Additionally, medical marijuana has been used as a treatment for glaucoma since the 1970s, as it has been reported that its properties decrease intraocular pressure (IOP). However, in 2014, the American Academy of Ophthalmology stated that due to marijuana’s short-term relief, it is not recommended for the treatment of glaucoma.  

Medical marijuana also features spasmolytic properties and helps with pain and numbness associated with various neurological conditions ―although related clinical trials are still being conducted to make a stronger case. Plus, apart from alleviating chronic pain, CBD is also known for its effectiveness in easing anxiety symptoms and insomnia.  

Myths and facts about medical marijuana 

Unfortunately, there are still some common misconceptions about the differences between recreational and medical use and many myths to be debunked. Let’s see some of the most persistent ones.  

Myth: Medical marijuana will get you stoned 

Fact: As mentioned above, most medical marijuana products contain a low THC percentage, so there is no “high.” CBD products are also available without a prescription as it’s an herbal substance that doesn’t contain any intoxicating compounds.  

On the other hand, THC is a psychoactive compound, meaning it can alter perceptions and mood. When administered by an authorized professional in tiny and regulated doses, it can help with the relief of many symptoms, but those doses won’t get you “stoned.”   

Myth: If you take medical marijuana, you’ll become addicted 

Fact: Like any other medicine, medical marijuana can be abused. However, even though a lot of people, as well as the National Institute on Drug Abuse, claim that marijuana can be considered a “gateway drug” leading to harder narcotics use, as far as medical use is concerned, that could only be a risk for frequent, high-THC doses administered to users prone to abuse and addiction.  

Myth: You have to smoke medical marijuana 

Fact: There are many consumption methods for medical marijuana, and smoking or vaping are only an example ―even though it’s the most popular way due to the quick onset of effects.  

Medical marijuana also comes in edibles and drinks, like gummies, tinctures, and teas ―those take longer to work. However, the best alternative for non-smokers is topical products, such as transdermal patches, lotions, and creams, gels, sprays, and oils, best for patients dealing with muscle and joint pain.  

Myth: Marijuana is an unsuitable substance for your body 

Fact: Actually, humans have a built-in endocannabinoid system, naturally producing some of its own cannabinoids! When the marijuana compounds enter your body, this system’s receptors act like neurotransmitters, sending messages throughout the nervous system and enhancing the beneficial effects.   

As for the anxiety-related symptoms, our internal cannabinoid receptors react to THC, which increases dopamine release, a neurotransmitter that creates pleasurable feelings.  

Myth: Any doctor can get you a prescription for medical marijuana 

Fact: Authorized health professionals can prescribe you medical marijuana if deemed necessary. However, the administration of marijuana is controlled by your state’s authorities. You have to apply to the government to be registered as a medical cannabis patient by establishing proof of residency and qualifying conditions.   

Myth: Medical marijuana is a cure for various conditions 

Fact: Medical marijuana can be used to treat and alleviate various symptoms, but in no way can it be considered a cure. For example, it can ease many of the symptoms experienced by cancer patients, like pain and side effects from chemotherapy. Still, it should not be used solely as an alternative for conventional cancer treatments. In any case, a licensed health professional is to be advised before making changes to your medical therapy.  

Like any other medication, you must use medical marijuana in moderation to get the most out of it. But also, marijuana is basically herbal, so if you practice safe medicating, you will have even fewer problems than the side effects caused by chemical medicine.   


StaffMay 8, 2021


Editors Note: This is a guest post.

Vaping and CBD are two topics that are becoming more popular among those who use them. When you vape, the main difference is that you don’t get any harmful smoking particles that go into your lungs. It also has less smell if you decide on using them. 

A third way of consuming cannabis products is through the sublingual method. The rick simpson oil is a good product to try using this way. In fact, it is so popular that when I buy my weed online, most dispensaries have already sold out of this product. CBD in a nutshell is found in marijuana plants. It is one of the two most common chemicals found along with THC. To put it simply, CBD and THC are the exact same other than the fact that THC gets you high, while CBD does not.

Remember, if you want to get high, use THC. If you just want cannabis benefits, use CBDBy following this simple rule, you can enjoy marijuana in a good and responsible way. I know many people who use CBD just for health-related issues. We really should get rid of the negative connotation that everyone who uses weed is an addict.

Usually, CBD products will contain less than 0.3% of THC. There are also CBD products such as the CBD extract capsules that have zero THC. These products can be bought from a Canadian mail order cannabis store and they usually have many options as well. Yes, we know that there are some laws in certain places that make CBD illegal. However, as mentioned before, the laws for CBD are slowly changing as people become more accepting of it. Also, you should be cautious about where you are buying CBD oil. If you are buying from a shady dispensary, it could spell trouble for you.

For all you know, the packaging may not even show the accurate amount of CBD. This can lead to getting too much cannabis in your body which is not ideal. By buying from trusted places only, you reduce the risks of using cannabis-related products in general. Just think about how you only buy medicine from trusted places. You would not buy it from some random guy on the street, would you? In the same way, do not buy CBD or any vape products from anyone you do not know. A legal place will provide you with the highest quality products available. 

Although it may be more pricey, it is worth the extra money to have the peace of mind that you are getting good CBD only.

Vaping CBD Oil : How Safe Is It? 

When people vape a THC vape pen, they usually want instant effects of what they are inhaling. However, knowing the effects vaping CBD oil is always a good thing to know. The more knowledge you have about this, the better it is for you. There is actually not much research done on the long term effects of vaping CBD oil. So, just remember that too much of anything is never a good thing. Fruits may be healthy for you but if you eat too much of it, you will not feel well. Water is good for you but too much of it can make your blood diluted. Nowadays, we see so many youngsters starting to smoke and vape. It is important that they know the consequences vaping can do to their body.

Nevertheless, vaping is still much better than smoking. There is no smoke that enters your lungs. Also, some places may be selling products that they claim to have CBD oil only. However, it may also contain other harmful materials. With no set guideline on how much CBD is suitable to use at one time, it makes it a little unsafe for those who don’t take any precaution.

Bonus Offer For Our Readers

You have now learned about the relationship between CBD oil and vaping.

As a bonus for reading this article, this mail order dispensary is offering Canadian edibles at amazing prices. Their price-match and satisfaction guarantee makes it really risk-free to try their cannabis products! Unfortunately, they only sell in Canada only. But this is good news for our Canadian readers! In the end, if you decide to use CBD oil when vaping, do so on your own time and not give in to any peer pressure. In this way, you won’t fall into the trap of taking too much to the point that it may be harmful to your body.


StaffMay 7, 2021


Editors Note: This is a guest post.

Some people like to smoke cannabis, others like to eat it—and some like to vaporize it! As places around the world continue to legalize cannabis, businesses are realizing the opportunities to be had in this growing market. 

Each year, consumers look forward to innovations in technology. When it comes to cannabis vapes, the market is booming with new devices and tweaks to existing products. Entrepreneurs don’t want to miss the opportunity to create the next best vape.

Cannabis vape tech is taking off globally, and here are 3 reasons why:

Demand is Increasing

During the pandemic, many consumers have reported that their medical use of cannabis for mental health reasons has increased. In addition, more and more states are legalizing the medical and recreational use of cannabis. To meet the rising demand, and to accommodate new consumers, vaping technology is advancing rapidly.

Whether consumers prefer to use dry flower or oil in their vapes, there’s a device on the market designed to meet their needs. Pods, pens, and box mods—you name it, there’s a cannabis vape for it. Now that demand is increasing for cannabis vapes, new products are being designed to accommodate it.

To gain a competitive edge in the market, there are new vaporizers coming out. Some utilize technology for a more user-friendly experience, like disposable or pre-filled vapes. Others focus on sustainability to appeal to eco-conscious consumers. Features like longer battery life, self-cleaning, and shatter-resistant casing will set cannabis vapes apart in a saturated market.

Producers are always racing to meet the needs of the market, and in 2021, the market is full of opportunities for innovative vape devices. Given how recently cannabis was legalized in many states and countries, there’s plenty of room for growth—the question is, who will capitalize on it first?

Fewer Consumers are Smoking

Given the global outbreak of respiratory illness, more consumers are moving away from smoking and gravitating towards vapes. When cannabis is vaporized, it’s consumed at a lower temperature than when it’s smoked. If cannabis is smoked, it will cause combustion, which can produce harmful byproducts. The consumer is not exposed to these chemicals when cannabis is vaporized.

As public awareness about the respiratory issues associated with smoking increases, vaping is on the rise. Not only does vaping cannabis help consumers give up smoking, but the devices are more discreet and easy to use.

Someone who’s transitioning from smoking to vaping may be unsure of where to begin. There are different vapes to start with for new users, designed for ease of use. These include pens, pods, and disposable vapes. As more and more consumers switch to vaping, we expect to see user-friendly devices become increasingly popular.

There has never been a better time to quit smoking than right now, when COVID-19 is still making waves around the globe. The fate of the cannabis market seemed uncertain at the beginning, but now the trend is clear: vaping cannabis is on the rise.

Vape Tech Producers are Partnering with Cannabis Cultivators

There’s one main barrier to producing new vape technology: state regulations. With the implementation of PMTA (Premarket Tobacco Application) looming over the tobacco vaping industry, some worry that cannabis vapes will be the next target.

To counteract these issues, companies are moving away from producing cannabis and devices. Instead, they are only producing vapes and relying on partnerships with popular cannabis cultivation companies. Businesses can specialize in creating cannabis tech without being held up by the licenses and regulations associated with cultivation. 

By partnering with cannabis producers, vape manufacturers can place their sole focus on improving their products. They don’t need to worry about obtaining licenses if they partner with companies that already have them; instead, they can work on releasing the next innovative vape.

When businesses focus their resources exclusively on advancing the technology of vaporizers, advancements can be made that will transform the vaping industry.


Cannabis vape producers are trying to match the fast pace of the market in 2021. In recent years, there’s been an influx of cannabis consumers interested in vaping, and the pandemic has only accelerated that trend. 

We anticipate that as the demand for cannabis vaporizers increases, the technology will develop rapidly to appeal to new and seasoned vapers alike.


StaffMay 7, 2021


Editors Note: This is a collaborative post.

CBD capsules are one of the most popular ways to take CBD. They are a clean, efficient, and familiar administration method. Unfortunately, there is not is a lack of understanding of how much each individual should be taking.

The confusion is due to two reasons. First, we do not have a sufficient amount of research regarding CBD. While we have seen a recent influx of human trials using CBD, we are far from the position we need to fully understand the amount of CBD required for a specific condition. Second, we each metabolize CBD differently. One amount may work for someone but not affect another person.

What are CBD Capsules?

A capsule is a gelatin container that keeps CBD escaping in a pill form. The CBD powder is inside the tablet that is easily swallowed and absorbed into the stomach.

CBD softgels are another popular form of CBD delivery. Instead of a capsule, the CBD oil is suspended in a clear gel, also designed to be swallowed and absorbed readily. CBD softgels 25mg are a common dose. Many people like the softgel over the capsule because they usually contain an oil rather than a powder.

CBD Oil or Capsules

Most people are more comfortable swallowing a pill than taking CBD sublingually. The taste of CBD oil also can be off-putting. Hemp has a strong earthy flavor that can take some getting used to. CBD oils capsules are swallowed, allowing the consumer to avoid any unpleasant taste, getting their daily dose.

CBD oil has higher bioavailability, meaning more CBD will be available for the body to utilize after ingesting. Bioavailability is essential, but it does not matter if you are not consistently dosing. If CBD oil turns you off and keeps you from getting your daily dose, the amount that is used by the body is irrelevant.

CBD Capsules Dosage

Most studies are observing people using CBD look at a dosage between 25-75mg. A typical dose given in retail products is also 25mg. This amount is a low threshold that most researchers and CBD companies choose to give their patients or customers.

While 25mg is a typical dose, many people taking CBD capsules for the first time may want to start smaller. The freedom to choose your amount is the most significant disadvantage to carrying CBD in capsule or softgel form. You are not able to lower the dose. If you aren’t comfortable taking a full dose just yet, find a company selling microdoses of 5-10mg before going up to an entire 25mg.

CBD is tolerated well by humans and does not have any adverse side effects. However, some people may still be intimidated by taking 25mg capsules. It may be more difficult to find, but there are options online for users wanting a smaller dose.

When to Take CBD?

The timing of CBD is also not entirely understood. Some studies suggest taking CBD at night if your goal is to overcome sleeping disorders and in the day if you are experiencing pain or a mental health condition. The most important part of taking CBD is to dose regularly. Taking CBD only once will not have much effect. A steady amount is the only way to experience the benefits.

Take CBD on a full stomach, especially if you are taking CBD capsules. The absorption rate will be much higher than if you were to take CBD without eating. If you are experiencing trouble sleeping and hope CBD can impact, take 30-45 minutes before going to bed. We recommend taking your CBD capsules right after your first meal for those suffering from mental health conditions.

StaffMay 6, 2021


It’s time for your Daily Hit of cannabis financial news for April 6, 2021.

On the Site


After the market closed on Wednesday, Innovative Industrial Properties, Inc. (IIP) (NYSE: IIPR) delivered another quarter of solid results. The real estate investment trust (REIT) reported that its total revenues increased 103% to $42.9 million for the first quarter ending March 31, 2021. This beat the yahoo Finance average analyst estimate for revenues of $42.88 for the quarter.

IIP also recorded net income of approximately $25.6 million for the quarter, or $1.05 per diluted share, and adjusted funds from operations (“AFFO”) of approximately $38.4 million, or $1.47 per diluted share (Note: AFFO per diluted share for the period includes the dilutive impact of the assumed full exchange of IIP’s $143.75 million of exchangeable senior notes for shares of common stock). This also beat the analyst estimate for $0.96. In addition, IIP paid a quarterly dividend of $1.32 per share on April 15, 2021, to common stockholders of record as of March 31, 2021, representing a 32% increase over the first quarter of 2020’s dividend and an approximately 6% increase over the fourth quarter 2020 dividend. 


While millions of Americans are getting ready to enjoy the summer for the first time in over a year, the cannabis industry is already gearing up for the upcoming fall harvest. Taking place between October and early November, the period is called Croptober, and it is a time when roughly 80%-85% of the cannabis industry’s outdoor cannabis is harvested. 

The reason why the industry harvests the majority of outdoor cannabis during this specific period has to do with the plant itself. Cannabis is an annual plant, which means it lives out its entire life cycle in a single growing season. 

In Other News


The Alabama House of Representatives voted in favor (68-34-1) of the Compassion Act (SB 46), a bill that would allow registered patients with qualifying conditions to safely access and use medical cannabis. This marks the first time the Alabama House has considered a medical cannabis bill. A full summary of SB 46 is available here.

While SB 46 was previously passed by the full Senate, the bill was amended in the House. The bill will need to return to the Senate for final consideration before it can be sent to the governor’s desk. 

Karen O’Keefe, director of state policies at the Marijuana Policy Project said, “Passing the Compassion Act will allow seriously ill patients to finally get the relief they deserve. Alabama is one of only 14 states in the country that continues to criminalize the medical use of cannabis, and while this bill is more restrictive than is ideal, it is a dramatic improvement from the status quo and would improve the lives of thousands of Alabamians. We urge the Senate to swiftly concur with the modified bill, and Gov. Ivey to sign it into law.”


Trulieve Cannabis (TCNNF -3.9%) has completed the previously announced acquisition of Mountaineer Holding, expanding the Florida-based company’s presence in West Virginia. The total consideration of the deal at $6M consisted of $3M in cash and the issuance of ~60.3K of Trulieve shares.Commenting on the transaction, Trulieve CEO Kim Rivers said: “The addition of Mountaineer achieves a significant presence for us in West Virginia.” The Mountaineer owns a cultivation permit, and two dispensary permits in the state.“We look forward to serving West Virginia patients, and expect to be operational before the end of 2021,” she added.Trulieve more than doubled its revenue in 2020 to $521.5M, yet like other U.S.-based cannabis stocks are weighed down by federal illegality of marijuana, noted a recent cover story in Barron’s.

StaffMay 6, 2021


While millions of Americans are getting ready to enjoy the summer for the first time in over a year, the cannabis industry is already gearing up for the upcoming fall harvest. Taking place between October and early November, the period is called Croptober, and it is a time when roughly 80%-85% of the cannabis industry’s outdoor cannabis is harvested. 

The reason why the industry harvests the majority of outdoor cannabis during this specific period has to do with the plant itself. Cannabis is an annual plant, which means it lives out its entire life cycle in a single growing season. 

Planted in the early Spring, the cannabis plant starts to produce buds in Fall as the days start to shorten, typically becoming ready for harvest around mid-October. For outdoor cultivators, this is the only time of the year they will harvest their crop, so it is both a time of celebration and great stress.

In many of the parts of the country where cannabis cultivation is big business, like the fabled Emerald Triangle in Northern California, Croptober has taken on an air akin to many of the harvest festivals celebrated throughout the world. 

Cannabis farms often give tours, parties are thrown, and while consumers can’t pick buds off the plant like apples, there is an influx of cheap high-quality cannabis. It is this celebratory atmosphere that first attracted Case Mandel, the Co-Founder of Cannadips, to set up shop in Humboldt County.

“I first visited Humboldt County in 2003 when I right out of High School,” Mandel recalls. “There were so many beautiful farms and incredible cultivators. I was completely astounded.”

Cannadips CBD manufacturers a smokeless CBD pouch that works as a dipping alternative. With a retail footprint of 6,000 stores, Cannadips CBD is one of the area’s largest hemp manufacturers.  Cannadips also manufactures a cannabis pouch in Humboldt County as well.

Looking to draw more attention to the season, Cannadips recently announced its first annual Croptober Getaway Sweepstakes where five winners are given an all-expenses-paid trip to Humboldt County to experience some of California’s most prominent cannabis farms and experience Croptober first-hand. The winners will also be treated to a party at the historic Arcata Theater Lounge, as well as a relaxing tour of Humboldt Count’s redwood forests and beaches. 

“Humboldt is not what they see on Netflix’s Murder Mountain or Dateline NBC, it’s the Emerald Triangle, we are excited to share its shine.”

The contest runs from May 1 to June 30, and those interested in signing up can register on the Cannadips website. Four of the winners will be chosen through a random drawing, with one winner to be announced every two weeks. The fifth winner will be the person with the best Instagram post with the #Croptober2021 hashtag.

“This type of access would never have been possible in the last twenty years,” says Mandel. “These Croptober winners won’t be touring corporate cannabis monocrops, they’ll be exploring the best outdoor sun-grown cannabis from some of Humboldt’s best cultivators.  It is refreshing we can share the amazing innovation and craft legally that has made our region famous.”


Don't Miss This Week's Groundbreaking News

Join the thousands of subscribers who stay informed with GMR's exclusive news briefs delivered directly to your inbox every Friday afternoon.

We respect your privacy. See our privacy policy.

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

@GreenMarketRpt – 1 day

New Report from ⁦@headset_io⁩ Says Medical Cannabis Consumers Spend More. New story from ⁦@julsaitch⁩

@GreenMarketRpt – 1 day

Yowza. Be careful when investing in crowdfunding deals. SEC files complaint against CEO and others for…

Back to Top